Iron-based phosphate binders - A new element in management of hyperphosphatemia

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 1, 2016, Pages 115-127

  Pai, Amy Barton ^a   Jang, Soo Min ^a   Wegrzyn, Nicole ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

ferric citrate; hyperphosphatemia; phosphate binders; sucroferric hydroxyoxide

Indexed keywords

ALUMINUM HYDROXIDE; ANTIANEMIC AGENT; ATORVASTATIN; CALCIUM ACETATE; CALCIUM CARBONATE; CIPROFLOXACIN; DIGOXIN; FERRIC AMMONIUM CITRATE; FERRIC CITRATE; FUROSEMIDE; HEMOGLOBIN; IRON; IRON BASED PHOSPHATE BINDING AGENT; LANTHANUM CARBONATE; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM CARBONATE; OMEPRAZOLE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; SEVELAMER; SEVELAMER CARBONATE; SIMVASTATIN; SUCROFERRIC OXYHYDROXIDE; TRANSFERRIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D DERIVATIVE; WARFARIN; DRUG COMBINATION; FERRIC ION; PHOSPHATE; SUCROSE;

ABDOMINAL PAIN; ABNORMAL FECES; ANEMIA; AREA UNDER THE CURVE; BLOATING; CHEWABLE TABLET; CHRONIC KIDNEY DISEASE; CONSTIPATION; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL ABSORPTION; HEADACHE; HEALTH CARE COST; HEARTBURN; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITALIZATION COST; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTENSION; INCREASED APPETITE; INTESTINE FLORA; LONG TERM CARE; LOSS OF APPETITE; MAXIMUM PLASMA CONCENTRATION; MUSCLE CRAMP; MUSCLE SPASM; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PAIN; PEPTIC ULCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; STOMACH PAIN; STOMACH ULCER; TASTE DISORDER; TIME TO MAXIMUM PLASMA CONCENTRATION; UNITED STATES; VOMITING; XEROSTOMIA; ANIMAL; BLOOD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; COMPLICATION; DRUG COMBINATION; MEDICATION COMPLIANCE; METABOLISM;

ANIMALS; DRUG COMBINATIONS; FERRIC COMPOUNDS; HUMANS; HYPERPHOSPHATEMIA; MEDICATION ADHERENCE; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; SEVELAMER; SUCROSE;

EID: 84954361358     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2016.1110573     Document Type: Review

References (68)

1. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;19:1489-1496.
2. Yusuf AA, Howell BL, Powers CA, et al. Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D. Am J Kidney Dis. 2014 Nov;64(5):770-780.
3. Wills MR, Savory J. Aluminum poisoning: dialysis encephalopathy, osteomalacia, and anaemia. Lancet. 1983;1:29-34.
4. Spiegel DM, Farmer B, Smits G, et al. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. J Ren Nutr. 2007;17(6):416-422.
5. Umanath K, Sika M, Niecestro R, et al. Rationale and study design of a three-period, 58 week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemo Int. 2013;17:67-74.
6. Chertow GM, Burke SK, Raggi P, et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245-252.
7. Lewis JB, Sika M, Koury MJ, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2015 Feb;26(2):493-503.
8. Barton Pai A, Conner TA, McQuade CR. Therapeutic use of the phosphate binder lanthanum carbonate. Expert Opin Drug Metab Toxicol. 2009 Jan;5(1):71-81.
9. Floege J, Covic AC, Ketteler M, et al. A phase III study of efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014 Sep;86 (3):638-647.
10. Salusky IB, Foley J, Nelson P, et al. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med. 1991;324:527-531.
11. Parkinson IS, Ward MK, Feest TG, et al. Fracturing dialysis osteodystrophy and dialysis encephalopathy: an epidemiological survey. Lancet. 1979;1:406-409.
12. Chertow GM, Raggi P, Chasan-Taber S, et al. Determinants of progressive vascular calcification in hemodialysis patients. Nephrol Dial Transpl. 2004;19:1489-1496.
13. Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and highcalcium diets. Kidney Int. 2012 Jun;81 (11):1116-1122.
14. Raggi P, Vukicevic S, Moysés RM, et al. Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol. 2010 Jan;5(Suppl 1): S31-S40.
15. Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coro-nary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008;51:952-965.
16. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815-1824.
17. Shantouf R, Budoff MJ, Ahmadi N, et al. Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol. 2008;28:275-279.
18. Ferreira A, Frazao JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008;19:405-412.
19. Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23 (8):1407-1415.
20. Haratake J, Yasunaga C, Ootani A, et al. Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate. Am J Surg Pathol. 2015 Jun;39 (6):767-771.
21. Hutchison AJ, Barnett ME, Krause R, et al. SPD405-309 lanthanum study group. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract. 2008;110:c15-c23.
22. Nastou D, Fernandez-Fernandez B, Elewa U, et al. Next-generation phosphate binders: focus on iron-based binders. Drugs. 2014;74:863-877.
23. Lanz M, Baldischweiler J, Kriwet B, et al. Chewability testing in the development of a chewable tablet for hyperphosphatemia. Drug Dev Ind Pharm. 2014 Dec;40 (12):1623-1631.
24. Ferric citrate tablets new drug application [Internet]. [cited 2015 Jan 8]. Available from: http://www.accessdata.fda.gov/drug satfda-docs/nda/2014/ 205874Orig1s000TOC.cfm
25. Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Neph. 2010;74(1):4-11.
26. Wuthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8:280-289.
27. Floege J, Covic AC, Ketteler M, et al. Long-term effects of iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015 Feb 16.
28. Sinsakul M, Sika M, Koury M, et al. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract. 2012;121:c25-c29.
29. Dwyer JP, Sika M, Shulman G, et al. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis. 2013;61 (5):759-766.
30. Wilhelm M, Gaillard S, Rakov V, et al. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin Neph. 2014;81 (4):251-258.
31. Product Information: VELPHORO(R) oral chewable tablets, sucroferric oxyhydroxide oral chewable tablets. Waltham, MA: Fresenius Medical Care North America (per manufactuer); 2013.
32. Liu SH, Chu HI. Studies of calcium and phosphorus metabolism with special reference to pathogenesis and effects of dihydrotachysterol (A.T.10) and iron. Medicine (Baltimore). 1943;22:103-161.
33. Liu SH, Chu HI, Hsu HC, et al. Calcium and phosphorus metabolism in osteomalacia. J Clin Invest. 1941;20:255-271.
34. Cox G, Dodds M, Wigman H, et al. The effects of high doses of aluminum and iron on phosphorus metabolism. J Biol Chem. 1931;92:11-12.
35. Rehm P, Winters J. The effect of ferric chloride on the utilization of calcium and phosphorus in the animal body. J Nutr. 1940;19:213-222.
36. Hsu CH, Patel SR, Young EW. New phosphate binding agents: ferric compounds. J Am Soc Nephrol. 1999;10:1274-1280.
37. Rosenbaum DP, Holmes-Farley SR, Mandeville WH, et al. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol Dial Transplant. 1997;12(5):961-964.
38. Iida A, Kemmochi Y, Kakomoto K, et al. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol. 2013;37:346-358.
39. IUPAC. Compendium of chemical terminology [Internet]. 2nd ed. [cited 2015 Jan 8]. Available from: http://goldbook.iupac. org/C01329.html
40. Francis AJ, Dodge CJ. Influence of complex structure on the biodegradation of iron-citrate complexes. Appl Environ Microbiol. 1993;59(1):109-113.
41. Cutler C, Bravo A, Ray AD, et al. Iron loading into ferritin can be stimulated or inhibited by the presence of cations and anions: a specific role for phosphate. J Inorg Biochem. 2005 Dec;99 (12):2270-2275.
42. Chong E, Kalia V, Willsie S, et al. Drug- drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects. J Nephrol. 2014;27(6):659-666.
43. Levesque V, Chong EMF, Moneuse P. Posthoc analysis of pharmacodynamic interaction of PA21 with statins in a phase 3 study of PA21 in dialysis patients with hyperphosphatemia [abstract]. Atlanta, GA: American Society of Nephrology Renal Week; 2013.
44. Rastogi A. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease. Ther Adv Cardiovasc Dis. 2013 Dec;7(6):322-342.
45. Rastogi A, Covic A, Floege J, et al. No clinically relevant changes in vitamin D concentrations with PA21 (sucroferric oxyhydroxide; Velphoro®), a novel ironbased phosphate binder, over 52 weeks [abstract]. National Kidney Foundation 2014 Clinical Meeting, Las Vegas, NV.
46. Fraser WD. Vitamin D assays: past and present debates, difficulties, and developments. Calcif Tissue Int. 2013 Feb;92 (2):118-127.
47. Auryxia prescribing information [Internet]. [cited 2015 Jan 8]. Available from: http:// auryxia.com/wp-content/uploads/Auryxia- PI-Keryx-112014.pdf
48. Cullen E, Dange M, Jabs K, et al. In vitro drug-drug interaction study with KRX- 0502 (ferric citrate) and four test drugs [Poster T2287]. Presented at the American Association of Pharmaceutical Scientists Annual Meeting and Exposition; 2014 Nov 2-6; San Diego, CA.
49. Horn JR, Mantione MM, Johanson JF. OTC polyethylene glycol 3350 and pharmacists' role in managing constipation. J Am Pharm Assoc (2003). 2012 May- Jun;52(3):372-380.
50. Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg. 1995;82(2):216-222.
51. Mutell R, Rubin JL, Bond TC, et al. Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model. Int J Nephrol Renovasc Dis. 2013;6:79-87.
52. Rodby R, Umanath K, Niecestro R, et al. Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Expert Rev Pharmacoecon Outcomes Res. 2015 Jun;15(3):545-550.
53. Umanath K, Jalal DI, Greco BA, et al. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol. 2015 Oct;26 (10):2578-2587.
54. Charytan DM, Pai AB, Chan CT, et al. On behalf of the American Society of Nephrology Dialysis Advisory Group. Considerations and challenges in defining the optimal utilization of iron in dialysis-dependent chronic kidney disease. J Am Soc Nephrol. 2015 Jun;26 (6):1238-1247.
55. Willhite CC, Karyakina NA, Yokel RA, et al. Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts. Crit Rev Toxicol. 2014 Oct;44(Suppl 4):1-80.
56. Drüeke TB. Intestinal absorption of aluminium in renal failure. Nephrol Dial Transplant. 2002;17(Suppl 2):13-16.
57. Gupta A. Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity. Pharmaceuticals (Basel). 2014;7 (10):990-998.
58. Coburn JW, Mischel MG, Goodman WG, et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis. 1991 Jun;17 (6):708-711.
59. Van Buren PN, Lewis JB, Dwyer JP, et al. The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: results from prespecified analyses of a randomized clinical trial. Am J Kidney Dis. 2015 Sep;66(3):479-488.
60. Nitta K, Nagano N, Tsuchiya K. Fibroblast growth factor 23/klotho axis in chronic kidney disease. Nephron Clin Pract. 2014;128 (1-2):1-10.
61. Kocełak P, Olszanecka-Glinianowicz M, Chudek J. Fibroblast growth factor 23- structure, function and role in kidney diseases. Adv Clin Exp Med. 2012 May- Jun;21(3):391-401.
62. Sprague S, Covic A, Ketteler M, et al. Analysis of CKD-MBD markers in a phase 3 study of PA21 and sevelamer in patients with hyperphosphatemia. J Am Soc Nephrol. 2013;24:755A.
63. Block GA, Fishbane S, Rodriguez M, et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5. Am J Kidney Dis. 2015;65(5):728-736.
64. Phan O, Maillard M, Peregaux C, et al. PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats. J Pharmacol Exp Ther. 2013;346:281-289.
65. Hansen TH, Gøbel RJ, Hansen T, et al. The gut microbiome in cardio-metabolic health. Genome Med. 2015;7(1):33.
66. Extending our view of self: the Human Gut Microbiome Initiative (HGMI). [cited 2015 Jan 4]. Available from: http:// www.genome.gov/Pages/Research/ Sequencing/SeqProposals/HGMISeq.pdf
67. Kortman GA, Raffatellu M, Swinkels DW, et al. Nutritional iron turned inside out: intestinal stress from a gut microbial perspective. FEMS Microbiol Rev. 2014 Nov;38(6):1202-1234.
68. Jefferies HJ, Crowley LE, Harrison LE, et al. Circulating endotoxaemia and frequent haemodialysis schedules. Nephron Clin Pract. 2014;128(1-2):141-146.